## Stefan Sturm

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9511152/publications.pdf

Version: 2024-02-01

1936888	1719596
4	7
h-index	g-index
8	265
ons times ranke	ed citing authors
	4 h-index

#	Article	IF	CITATIONS
1	Pharmacologic effects of oseltamivir in immunocompromised adult patients as assessed by population PK/PD analysis and drugâ€disease modelling for dosing regimen optimization. British Journal of Clinical Pharmacology, 2021, 87, 1359-1368.	1.1	4
2	Dosing regimen optimisation for oseltamivir in immunocompromised paediatric patients with influenza: Extrapolation of efficacy. British Journal of Clinical Pharmacology, 2021, , .	1.1	0
3	Pharmacokinetics and Pharmacodynamics of Conventional-Dose vs Triple-Dose Oseltamivir in Severely Immunocompromised Children With Influenza. Open Forum Infectious Diseases, 2019, 6, ofz430.	0.4	3
4	A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a $\langle i \rangle$ SMN2 $\langle i \rangle$ splicing modifier. British Journal of Clinical Pharmacology, 2019, 85, 181-193.	1.1	75
5	Results and evaluation of a firstâ€inâ€human study of RG7342, an mGlu5 positive allosteric modulator, utilizing Bayesian adaptive methods. British Journal of Clinical Pharmacology, 2018, 84, 445-455.	1.1	12
6	Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer's disease and elderly controls after oral administration of sembragiline. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 382-391.	3.3	21
7	No Evidence of QT Prolongation With Supratherapeutic Doses of Aleglitazar. Journal of Cardiovascular Pharmacology, 2012, 59, 288-297.	0.8	2
8	Metabolism, Excretion, and Pharmacokinetics of [14C]-Radiolabeled Aleglitazar: A Phase I, Nonrandomized, Open-Label, Single-Center, Single-Dose Study in Healthy Male Volunteers. Clinical Therapeutics, 2012, 34, 420-429.	1.1	6